" class="no-js "lang="en-US"> AML Archives - Medtech Alert
Monday, April 15, 2024

Sort by:


Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Mendus and NorthX Biologics to Enter into Strategic Cell Therapy Manufacturing Alliance Supported by New Investor Flerie

Mendus AB, a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announces that it […]

MEI Pharma Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib in Patients with Acute Myeloid Leukemia or B-Cell Malignancies

MEI Pharma, a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, has announced […]

Servier Receives European Commission approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma

Servier, a global pharmaceutical group, today announced that the European Commission (EC) has approved Tibsovo […]

CytoMed Therapeutics Announces Collaboration with MD Anderson Cancer Center

CytoMed Therapeutics, a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel […]

Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results of Iomab-B Showcased to the European Transplant Community

Actinium Pharmaceuticals, a leader in the development of targeted radiotherapies, today announced that the positive […]

Quizartinib NDA Review for Patients with Newly Diagnosed FLT3-ITD Positive AML Extended by FDA

Daiichi Sankyo has announced that the United States Food and Drug Administration (FDA) has extended […]

Actinium Signs Cooperative Research and Development Agreement with National Cancer Institute

Actinium Pharmaceuticals, a leader in the development of targeted radiotherapies, have announced that it has […]

STORM Therapeutics Presents STC-15 Preclinical Data Supporting Treatment of Patients with AML

STORM Therapeutics, the clinical-stage biotechnology company discovering and developing novel small molecule therapies targeting RNA […]

Priothera Announces First Patients Enrolled in Pivotal Global Study for Patients with Acute Myeloid Leukemia

Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more